1.Siegel R L , Miller K D , Jemal A . Cancer statistics, 2015[J]. CA: A Cancer Journal for Clinicians, 2015, 65(1):5-29.
2.Jeon S Y , Hwang K A , Choi K C . Effect of steroid hormones, estrogen and progesterone, on epithelial mesenchymal transition in ovarian cancer development[J]. The Journal of Steroid Biochemistry and Molecular Biology, 2016:S0960076016300188.
3.Lindsey A Torre, Britton Trabert, Carol E DeSantis. Ovarian cancer statistics, 2018.[J]. histopathology, 2018.
4.Xu X , Qiu J , Sun Y . The basics of CAR T design and challenges in immunotherapy of solid tumors — Ovarian cancer as a model[J]. Human Vaccines & Immunotherapeutics, 2017:1-8.
5.Whilding Lynsey M,Halim Leena,Draper Benjamin,Parente-Pereira Ana C,Zabinski Tomasz,Davies David Marc,Maher John. CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies.[J]. Cancers,2019,11(5).
6.Song D G , Ye Q , Santoro S , et al. Chimeric NKG2D CAR-Expressing T Cell-Mediated Attack of Human Ovarian Cancer Is Enhanced by Histone Deacetylase Inhibition[J]. Human Gene Therapy, 2013, 24(3):295-305.
7.Owens G L , Sheard V E , Kalaitsidou M , et al. Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer[J]. Journal of Immunotherapy, 2018, 41.
8.Schneider D , Xiong Y , Wu D , et al. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines[J]. Journal for ImmunoTherapy of Cancer, 2017, 5(1):42.
9.Lanitis Evripidis, Poussin Mathilde, Klattenhoff Alex W, Song Degang, Sandaltzopoulos Raphael,June Carl H,Powell Daniel J. Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused anti-tumor activity with reduced potential for toxicity in vivo.[J]. Cancer immunology research,2014,1(1).
10.Hegde M , Mukherjee M , Grada Z , et al. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape[J]. The Journal of clinical investigation, 2016, 126(8):3036-3052.
11.Wilkie S , Schalkwyk M C I , Hobbs S , et al. Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling[J]. Journal of Clinical Immunology, 2012, 32(5):1059-1070.
12.Felder M , Kapur A , Gonzalez-Bosquet J , et al. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress[J]. Molecular Cancer, 2014, 13(1):129.
13.Liu Q , Cheng Z , Luo L , et al. C-terminus of MUC16 activates Wnt signaling pathway through its interaction with β-catenin to promote tumorigenesis and metastasis[J]. Oncotarget, 2014, 7(24):36800-36813.
14.Taube J M , Anders R A , Young G D , et al. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape[J]. Science Translational Medicine, 2012, 4(127):127ra37-127ra37.
15.Zou W , Chen L . Inhibitory B7-family molecules in the tumour microenvironment[J]. NATURE REVIEWS IMMUNOLOGY, 2008, 8(6):467-477.
16.Abiko K , Matsumura N , Hamanishi J , et al. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer[J]. British Journal of Cancer, 2015, 112(9):1501-1509.
17.Qu Q X , Xie F , Huang Q , et al. Membranous and Cytoplasmic Expression of PD-L1 in Ovarian Cancer Cells[J]. Cellular Physiology and Biochemistry, 2017:1893-1906.
18.Cherkassky L, Morello A, Villena-Vargas J, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition[J].J Clin Invest. 2016 Aug 1;126(8):3130-44. Doi: 10.1172/JCI83092. Epub 2016 Jul 25.
19.Fan C , Reader J , Roque D M . Review of Immune Therapies Targeting Ovarian Cancer[J]. Current Treatment Options in Oncology, 2018, 19(12).
20.Peng W , Liu C , Xu C , et al. PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-γ Inducible Chemokines[J]. Cancer Research, 2012, 72(20):5209-5218.
21.Strickland K C , Howitt B E , Shukla S A , et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.[J]. Oncotarget, 2016, 7(12):13587-13598.
22.Abiko K, Mandai M, Hamanishi J, et al. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction.[J]. Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2013, 19(6):1363-1374.
23.Sui X , Ma J , Han W , et al. The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients[J]. Oncotarget, 2015, 6(23):19393-19404.
24.Marco R , Barrett D M , Kenderian S S , et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies[J]. Journal of Clinical Investigation, 2016, 126(10):3814-3826.
25.Sanchez, Eric, Smith, Emily J, Yashar, Moryel A, et al. The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma[J]. Targeted Oncology. http://kns.cnki.net/kcms/detail/61.1415.R.20190903.1344.172.html.
26.Ma Futian, Ho Jin-Yuan, Du Huan, Xuan Fan, Wu Xiaoli, Wang Qinglong, Wang Lin, Liu Ying, Ba Min, Wang Yizhuo, Luo Jianmin, Li Jianqiang. Evidence of Long-Lasting Anti-CD19 Activity of Engrafted CD19 Chimeric Antigen Receptor Modified T Cells in A Phase I Study Targeting Pediatrics with Acute Lymphoblastic Leukemia.[J]. Hematological oncology,2019.
27.Li Jie, Wu Zhenyu, Zhao Naiqing. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.[J]. Advances in therapy,2019.
28.Zhu X , Cai H , Zhao L , et al. CAR-T cell therapy in ovarian cancer: from the bench to the bedside[J]. Oncotarget, 2017, 8(38).
29.Teachey D T, Lacey S F, Shaw P A, et al. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia[J]. 2016, 6(6):664-679.
30.Wang Z , Han W . Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy[J]. Biomarker Research, 2018, 6(1):4.
31.Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124:188–95.
32.Ren J, Zhang X, Liu X, Fang C, Jiang S, June CH, Zhao Y. A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget. 2017; 8:17002–17011. http:// doi.org/10.18632/oncotarget.15218.
33.Cao Bihui,Liu Manting,Wang Lu,Liang Baoxia,Feng Yunfei,Chen Xiaopei,Shi Yuanyuan,Zhang Jinling,Ye Xiaodie,Tian Yu,Zhi Cheng,Li Junping,Lian Hui,Wu Qingde,Zhang Zhenfeng. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer.[J]. Biochemical and biophysical research communications,2020,524(1).